Follows pregnant people with obesity who take Wegovy, and their babies
Observes safety outcomes in pregnant people with obesity who took semaglutide.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
Key facts
- Where
- Madrid, SpainSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 50 years old?
Source: NCT05872022, who can take part
Where in Spain
- MadridMadrid, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT05872022
- Record updated
- 14 January 2026
- Original description
This is an observational, prospective Wegovy (semaglutide 2.4 milligram [mg]) Pregnancy Registry Study. The aim of this study is to compare the maternal, foetal, and infant outcomes of pregnant women who are exposed to Wegovy during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition with outcomes in an internal comparison cohort of pregnant women with obesity or overweight with at least one weight related comorbid condition at conception and who are not exposed to Wegovy or other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy. Infant outcomes will be assessed throughout the infant's first year of life, with active data collection by the registry occurring at 4 and 12 months after delivery.Read full original descriptionShow less
Wegovy® (Semaglutide 2.4 mg) Pregnancy Registry Study: A Prospective Cohort Study to Investigate Safety Outcomes of Exposure to Wegovy During Pregnancy
This is an observational, prospective Wegovy (semaglutide 2.4 milligram [mg]) Pregnancy Registry Study. The aim of this study is to compare the maternal, foetal, and infant outcomes of pregnant women who are exposed to Wegovy during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition with outcomes in an internal comparison cohort of pregnant women with obesity or overweight with at least one weight related comorbid condition at conception and who are not exposed to Wegovy or other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy. Infant outcomes will be assessed throughout the infant's first year of life, with active data collection by the registry occurring at 4 and 12 months after delivery.
Inclusion: Signed consent obtained before any study-related activities; Female 15-50 years of age at the time of signing consent; Currently or recently pregnant; Resident of country included in the study; Authorisation for her HCP(s) to provide data to the registry; Exposed to Wegovy cohort: Exposure to at least one dose of Wegovy at any time during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition; Unexposed to Wegovy cohort: Have obesity or overweight with at least one weight related comorbid condition at conception.
Exclusion: Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation; Unexposed to Wegovy cohort: Exposure to Wegovy or other GLP-1 RA at any time during pregnancy.